SONOMA PHARMACEUTICALS, INC. Cost of Revenue
SONOMA PHARMACEUTICALS, INC. (SNOA) reported Cost of Revenue of $3.83 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Cost of Sales
us-gaap:CostOfRevenue · last filed 2026-08-06
- SONOMA PHARMACEUTICALS, INC. cost of revenue for the quarter ending 2026-06-30 was $3.83M, a 50.10% increase year-over-year.
- SONOMA PHARMACEUTICALS, INC. cost of revenue for the quarter ending 2026-03-31 was $3.38M, a 51.84% increase year-over-year.
- SONOMA PHARMACEUTICALS, INC. cost of revenue for the quarter ending 2025-12-31 was $2.70M, a 17.65% increase year-over-year.
- SONOMA PHARMACEUTICALS, INC. cost of revenue for the quarter ending 2025-09-30 was $3.48M, a 57.08% increase year-over-year.
- SONOMA PHARMACEUTICALS, INC. cost of revenue for fiscal 2026 was $12.11M, a 37.30% increase from fiscal 2025.
- SONOMA PHARMACEUTICALS, INC. cost of revenue for fiscal 2025 was $8.82M.
- SONOMA PHARMACEUTICALS, INC. cost of revenue for fiscal 2019 was $10.09M, a 7.94% increase from fiscal 2018.
- SONOMA PHARMACEUTICALS, INC. cost of revenue for fiscal 2018 was $9.35M, a 30.61% increase from fiscal 2017.
| Period end | Cost of Revenue 3 month | Cost of Revenue 6 month | Cost of Revenue 9 month | Cost of Revenue 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.83M 10-Q · filed 2026-08-06 | $7.21M derived: sum of 2 quarters · filed 2026-08-06 | $9.91M derived: sum of 3 quarters · filed 2026-08-06 | $13.39M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $3.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-16 | $6.08M derived: sum of 2 quarters · filed 2026-06-16 | $9.56M derived: sum of 3 quarters · filed 2026-06-16 | $12.11M 10-K · filed 2026-06-16 |
| 2025-12-31 | $2.70M 10-Q · filed 2026-02-10 | $6.18M derived: sum of 2 quarters · filed 2026-02-10 | $8.73M 10-Q · filed 2026-02-10 | $10.96M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-09-30 | $3.48M 10-Q · filed 2025-11-04 | $6.04M 10-Q · filed 2025-11-04 | $8.26M derived: sum of 3 quarters · filed 2026-08-06 | $10.55M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $2.55M 10-Q · filed 2026-08-06 | $4.78M derived: sum of 2 quarters · filed 2026-08-06 | $7.07M derived: sum of 3 quarters · filed 2026-08-06 | $9.29M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $2.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-16 | $4.52M derived: sum of 2 quarters · filed 2026-06-16 | $6.74M derived: sum of 3 quarters · filed 2026-06-16 | $8.82M 10-K · filed 2026-06-16 |
| 2024-12-31 | $2.29M 10-Q · filed 2026-02-10 | $4.51M derived: sum of 2 quarters · filed 2026-02-10 | $6.60M 10-Q · filed 2026-02-10 | |
| 2024-09-30 | $2.22M 10-Q · filed 2025-11-04 | $4.30M 10-Q · filed 2025-11-04 | ||
| 2019-03-31 | $10.09M 10-K · filed 2019-07-01 | |||
| 2018-03-31 | $9.35M 10-K · filed 2019-07-01 | |||
| 2017-03-31 | $7.16M 10-K · filed 2018-06-26 | |||
| 2012-06-30 | $32.00K 10-Q/A · filed 2012-08-31 | |||
| 2011-06-30 | $20.00K 10-Q/A · filed 2012-08-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| enVVeno Medical Corp (NVNO) | United States | $0.006B | -0.48 |
| INTELLIGENT BIO SOLUTIONS INC. (INBS) | United States | $0.005B | |
| AETHLON MEDICAL INC (AEMD) | United States | $0.005B | |
| Co-Diagnostics, Inc. (CODX) | United States | $0.007B | -0.32 |
| Bluejay Diagnostics, Inc. (BJDX) | United States | $0.004B | |
| OSR Health, Inc. (OSRH) | United States | $0.004B | -0.75 |
| Adagio Medical Holdings, Inc. (ADGM) | United States | $0.004B | |
| Autonomix Medical, Inc. (AMIX) | United States | $0.004B | |
| Beyond Air, Inc. (XAIR) | United States | $0.003B | -0.01 |
| Vivos Therapeutics, Inc. (VVOS) | United States | $0.003B | -0.26 |